Bimzelx (bimekizumab-bkzx) — Highmark
Psoriatic Arthritis (PsA) – enthesitis and/or dactylitis associated
Initial criteria
- age ≥ 18 years
- diagnosis of enthesitis and/or dactylitis associated PsA
- prescribed by or in consultation with a rheumatologist or dermatologist
- therapeutic failure or intolerance to at least one NSAID or a local glucocorticoid injection, or all NSAIDs and all local glucocorticoid injections are contraindicated
- therapeutic failure or intolerance to at least one step 1 plan-preferred agent for PsA
Reauthorization criteria
- disease stability or beneficial response to therapy